Skip to Main Content

H​​ere is STAT’s biotech scorecard, our regular ledger of stock-moving biotech events, for the third quarter:

Late last month, Alnylam Pharmaceuticals reported positive, top-line results from its HELIOS-B clinical trial testing vutrisiran in an increasingly common heart disease called ATTR-CM. Detailed study results are being presented at the annual meeting of the European Society of Cardiology in late August. Those data should help answer lingering questions about vutrisiran’s benefit in ATTR-CM, including how the drug stacks up competitively against a rival medicine called acoramidis, made by BridgeBio Pharma.


Novo Nordisk is developing an obesity drug called monlunabant that is designed to block the cannabinoid receptor 1 (CB1) — a target in the body’s endocannabinoid system known to directly impact many physiological processes, including metabolism. Novo is already an obesity giant thanks to Wegovy, so expected results this quarter from a monlunabant Phase 2 study may only be incrementally important. But the data are likely to have much a greater impact on Skye Bioscience and Corbus Pharmaceuticals — smaller biotechs also developing their own CB1-targeted obesity drugs.

STAT+ Exclusive Story


This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Already have an account? Log in



Totals $468 per year

$39/month Get Started

Totals $468 per year



for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month



Save 15%

$399/year Get Started

Save 15%

11+ Users


Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users


Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.


STAT encourages you to share your voice. We welcome your commentary, criticism, and expertise on our subscriber-only platform, STAT+ Connect

To submit a correction request, please visit our Contact Us page.